Simplex Trading, LLC Otonomy, Inc. Transaction History

Simplex Trading, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	BUY	$0.07 - $0.23 $85 - $281	1,224 New	1,224 $0
Q2 2022 Aug 03, 2022	SELL	$1.72 - $2.51 $15,218 - $22,208	-8,848 Reduced 69.97%	3,798 $7,000
Q2 2021 Aug 12, 2021	SELL	$2.06 - $2.67 $160,224 - $207,669	-77,779 Reduced 86.01%	12,646 $28,000
Q1 2021 Apr 26, 2021	BUY	$2.49 - $6.23 $225,158 - $563,347	90,425 New	90,425 $230,000
Q3 2020 Oct 14, 2020	SELL	$3.16 - $4.36 $13,534 - $18,673	-4,283 Closed	0 $0
Q2 2020 Jul 13, 2020	BUY	$1.87 - $3.84 $7,917 - $16,258	4,234 Added 8640.82%	4,283 $15,000
Q1 2020 Apr 29, 2020	SELL	$1.58 - $4.06 $1,984 - $5,099	-1,256 Reduced 96.25%	49 $0
Q4 2019 Feb 05, 2020	BUY	$2.13 - $3.83 $2,779 - $4,998	1,305 New	1,305 $4,000
Q2 2019 Jul 26, 2019	SELL	$2.35 - $3.09 $810 - $1,066	-345 Closed	0 $0
Q1 2019 Apr 18, 2019	BUY	$1.8 - $2.97 $621 - $1,024	345 New	345 $0
Q1 2018 Apr 26, 2018	SELL	$4.05 - $6.1 $103,161 - $155,379	-25,472 Closed	0 $0
Q4 2017 Jan 10, 2018	SELL	$2.8 - $5.55 $5,611 - $11,122	-2,004 Reduced 7.29%	25,472 $141,000
Q3 2017 Oct 25, 2017	BUY	$3.2 - $20.8 $87,923 - $571,500	27,476	27,476 $89,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.